According to a report by Globe Newswire on August 13, Deep Tide TechFlow announced that NASDAQ-listed biotech company LIXTE Biotechnology Holdings (stock code: LIXT, LIXTW) has approved a strategic capital allocation plan to incorporate cryptocurrency into the company's reserve assets. The company plans to allocate up to 25% of its funds reserves to digital assets such as Bitcoin.
LIXTE indicates that the specific timing and scale of transactions will depend on market conditions and other strategic considerations. The company will hold cryptocurrency assets through fully compliant custodians, and all transactions will strictly adhere to relevant financial, legal, and auditing regulations. LIXTE Chairman and CEO Geordan Pursglove stated that this move aims to hedge existing reserve assets and create returns for shareholders.
